wwPDB validation report of PDB entry 2VNT

FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR

STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR

ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OFSER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS

CRYSTAL STRUCTURE OF HUMAN MICROUROKINASE IN COMPLEX WITH 2-AMINO-5-HYDROXY-BENZIMIDAZOLE

UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT464 COMPLEX

SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE

A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE

DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTSAT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190UPA)

UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-J435 COMPLEX

ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATINGBINDING OF ACTIVE SITE- DIRECTED SERINE PROTEASE INHIBITORS

UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI- 1D COMPLEX

PLASMINOGEN ACTIVATOR (UROKINASE-TYPE, KRINGLE DOMAIN) (U-PA K) (NMR, MINIMIZED AVERAGE STRUCTURE)

UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN- AMILORIDE COMPLEX

UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEX

LMW U-PA STRUCTURE COMPLEXED WITH EGRCMK ( GLU-GLY-ARG CHLOROMETHYL KETONE)

SUBSTITUTED 2-NAPHTHAMADINE INHIBITORS OF UROKINASE

UNKNOWN (QGG): 1- 7-SULPHOAMIDOISOQUINOLINYL GUANIDINE

HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS.

UROKINASE-TYPE PLASMINOGEN ACTIVATOR (E.C.3.4.21.73)
UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE

20191225.v01 (using entries in the PDB archive December 25th 2019)
geometric validation package for ligand chemistry in protein x-ray structures